The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis
Introduction : The biosimilar product Inflectra® has been approved by the European Medicine Agency (EMA) for the same indications as its reference drug, infliximab, based on studies in patients with rheumatic diseases. Thus far, there have not been enough data regarding its efficacy and safety in ul...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2017-09-01
|
| Series: | Gastroenterology Review |
| Subjects: | |
| Online Access: | https://www.termedia.pl/The-efficacy-and-safety-of-the-biosimilar-product-Inflectra-compared-to-the-reference-drug-Remicade-in-rescue-therapy-in-adult-patients-with-ulcerative-colitis,41,30724,1,1.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|